Mitchell E. Gross, MD, PhD

Title(s)Associate Professor of Clinical Medicine
SchoolKeck School of Medicine of Usc
Address12414 Exposition Blvd.
Off Campus
Los Angeles CA 90064
Phone+1 310 272 7640
vCardDownload vCard

    Collapse Biography 
    Collapse Awards and Honors
    1989Phi Beta Kappa
    UCSD/Revelle College Academic1990Leadership Award
    1994Alpha Omega Alpha
    1994Hewlett Packard Award for Excellence in Internal Medicine
    1997  - 2002Specialty Training Advanced Research Fellowship
    1999Amgen Fellowship Research Award
    1999Rhone Phoulenc Rorer Travel Award
    2001AACR-AFLAC Scholar in Training Award,
    2006Donna and Jesse Garber Award

    Collapse Overview 
    Collapse Overview
    Dr. Gross is research director of the USC Norris Westside Cancer Center and the Center for Applied Molecular Medicine. His overall research interest focuses on applying modern techniques relating to the study of genes and proteins (genomics and proteomics) on the clinical problems faced in treating patients with prostate cancer. A particular interest relates to the androgen receptor and relating proteins and pathways as key driving forces behind the development and treatment of prostate cancer. As a medical oncologist, his clinical activities are focused on therapeutic clinical trials incorporating both molecularly targeted and conventional therapies to the care of patients with prostate cancer. He serves as primary investigator on many multi-center phase 1 and 2 clinical trials

    Dr. Gross has earned degrees from the University of California, San Diego (B.A.), Baylor College of Medicine in Houston (M.D.), and the University of California, Los Angeles (Ph.D. Molecular Biology). He completed a residency in internal medicine and a fellowship in hematology and medical oncology at the UCLA Center for the Health Sciences.

    Collapse Research 
    Collapse Research Activities and Funding
    Selective Cancer Treatment Based on High Frequency Ultrasonic Beam
    NIH R21EB022932Sep 16, 2016 - Jul 31, 2018
    Role: Co-Principal Investigator
    Role of PIASy in Androgen Signaling and Prostate Cancer
    NIH K08DK064379Aug 21, 2002 - Jun 30, 2007
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. MRI Detection of Lymph Node Metastasis through Molecular Targeting of C-C Chemokine Receptor Type 2 and Monocyte Hitchhiking. ACS Nano. 2024 Jan 23; 18(3):2091-2104. Trac N, Chen Z, Oh HS, Jones L, Huang Y, Giblin J, Gross M, Sta Maria NS, Jacobs RE, Chung EJ. PMID: 38212302.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    2. Cell State and Cell Type: Deconvoluting Circulating Tumor Cell Populations in Liquid Biopsies by Multi-Omics. Cancers (Basel). 2023 Aug 03; 15(15). Welter L, Zheng S, Setayesh SM, Morikado M, Agrawal A, Nevarez R, Naghdloo A, Pore M, Higa N, Kolatkar A, Thiele JA, Sharma P, Moore HCF, Richer JK, Elias A, Pienta KJ, Zurita AJ, Gross ME, Shishido SN, Hicks J, Velasco CR, Kuhn P. PMID: 37568766; PMCID: PMC10417732.
      View in: PubMed   Mentions:
    3. Synthesis and anti-cancer potential of potent peripheral MAOA inhibitors designed to limit blood:brain penetration. Bioorg Med Chem. 2023 09 07; 92:117425. Jacobs MR, Olivero JE, Ok Choi H, Liao CP, Kashemirov BA, Katz JE, Gross ME, McKenna CE. PMID: 37544256.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    4. Immune biomarkers associated with COVID-19 disease severity in an urban, hospitalized population. Pract Lab Med. 2023 Aug; 36:e00323. Chambliss AB, Aljehani M, Tran B, Chen X, Elton E, Garri C, Ung N, Matasci N, Gross ME. PMID: 37649544; PMCID: PMC10462676.
      View in: PubMed   Mentions:
    5. In Vivo Non-Thermal, Selective Cancer Treatment With High-Frequency Medium-Intensity Focused Ultrasound. IEEE Access. 2021; 9:122051-122066. Tang Y, Chen LY, Zhang A, Liao CP, Gross ME, Kim ES. PMID: 35321234; PMCID: PMC8939762.
      View in: PubMed   Mentions: 1  
    6. Effect of Periodized Resistance Training on Skeletal Muscle During Androgen Deprivation Therapy for Prostate Cancer: A Pilot Randomized Trial. Integr Cancer Ther. 2021 Jan-Dec; 20:15347354211035442. Dawson JK, Dorff TB, Tuzon C, Rice JC, Schroeder ET, Lane CJ, Gross ME, Dieli-Conwright CM. PMID: 34301165; PMCID: PMC8312192.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    7. CCR2-targeted micelles for anti-cancer peptide delivery and immune stimulation. J Control Release. 2021 01 10; 329:614-623. Trac N, Chen LY, Zhang A, Liao CP, Poon C, Wang J, Ando Y, Joo J, Garri C, Shen K, Kani K, Gross ME, Chung EJ. PMID: 33011241; PMCID: PMC8491563.
      View in: PubMed   Mentions: 14     Fields:    Translation:AnimalsCells
    8. Phase 2 trial of monoamine oxidase inhibitor phenelzine in biochemical recurrent prostate cancer. Prostate Cancer Prostatic Dis. 2021 03; 24(1):61-68. Gross ME, Agus DB, Dorff TB, Pinski JK, Quinn DI, Castellanos O, Gilmore P, Shih JC. PMID: 32123315; PMCID: PMC7483294.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCTClinical Trials
    9. Monitoring dynamic cytotoxic chemotherapy response in castration-resistant prostate cancer using plasma cell-free DNA (cfDNA). BMC Res Notes. 2019 May 15; 12(1):275. Patsch K, Matasci N, Soundararajan A, Diaz P, Agus DB, Ruderman D, Gross ME. PMID: 31092276; PMCID: PMC6521434.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    10. Randomized Phase II Trial of Abiraterone Alone or With Dasatinib in Men With Metastatic Castration-resistant Prostate Cancer (mCRPC). Clin Genitourin Cancer. 2019 08; 17(4):241-247.e1. Dorff TB, Quinn DI, Pinski JK, Goldkorn A, Sadeghi S, Tsao-Wei D, Groshen S, Kuhn P, Gross ME. PMID: 31227432; PMCID: PMC7446934.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCellsCTClinical Trials
    11. Effect of Monoamine oxidase A (MAOA) inhibitors on androgen-sensitive and castration-resistant prostate cancer cells. Prostate. 2019 05; 79(6):667-677. Gaur S, Gross ME, Liao CP, Qian B, Shih JC. PMID: 30693539; PMCID: PMC7462252.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCells
    12. Loss of ER retention motif of AGR2 can impact mTORC signaling and promote cancer metastasis. Oncogene. 2019 04; 38(16):3003-3018. Tiemann K, Garri C, Lee SB, Malihi PD, Park M, Alvarez RM, Yap LP, Mallick P, Katz JE, Gross ME, Kani K. PMID: 30575818; PMCID: PMC7523706.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansAnimalsCells
    13. Identification, characterization and application of a new peptide against anterior gradient homolog 2 (AGR2). Oncotarget. 2018 Jun 08; 9(44):27363-27379. Garri C, Howell S, Tiemann K, Tiffany A, Jalali-Yazdi F, Alba MM, Katz JE, Takahashi TT, Landgraf R, Gross ME, Roberts RW, Kani K. PMID: 29937991; PMCID: PMC6007958.
      View in: PubMed   Mentions: 6     Fields:    
    14. Loss of MAOA in epithelia inhibits adenocarcinoma development, cell proliferation and cancer stem cells in prostate. Oncogene. 2018 09; 37(38):5175-5190. Liao CP, Lin TP, Li PC, Geary LA, Chen K, Vaikari VP, Wu JB, Lin CH, Gross ME, Shih JC. PMID: 29844571; PMCID: PMC7500062.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansAnimalsCells
    15. Impact of resistance training on body composition and metabolic syndrome variables during androgen deprivation therapy for prostate cancer: a pilot randomized controlled trial. BMC Cancer. 2018 04 03; 18(1):368. Dawson JK, Dorff TB, Todd Schroeder E, Lane CJ, Gross ME, Dieli-Conwright CM. PMID: 29614993; PMCID: PMC5883585.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCTClinical Trials
    16. Protein Mimetic and Anticancer Properties of Monocyte-Targeting Peptide Amphiphile Micelles. ACS Biomater Sci Eng. 2017 Dec 11; 3(12):3273-3282. Poon C, Chowdhuri S, Kuo CH, Fang Y, Alenghat FJ, Hyatt D, Kani K, Gross ME, Chung EJ. PMID: 29302619; PMCID: PMC5749269.
      View in: PubMed   Mentions: 13     Fields:    
    17. Safety and Efficacy of Docetaxel, Bevacizumab, and Everolimus for Castration-resistant Prostate Cancer (CRPC). Clin Genitourin Cancer. 2017 Jul 14. Gross ME, Dorff TB, Quinn DI, Diaz PM, Castellanos OO, Agus DB. PMID: 28826933; PMCID: PMC7444943.
      View in: PubMed   Mentions: 6     Fields:    
    18. A pilot randomised controlled trial of a periodised resistance training and protein supplementation intervention in prostate cancer survivors on androgen deprivation therapy. BMJ Open. 2017 Jul 10; 7(7):e016910. Kiwata JL, Dorff TB, Todd Schroeder E, Salem GJ, Lane CJ, Rice JC, Gross ME, Dieli-Conwright CM. PMID: 28698349; PMCID: PMC5726104.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    19. Automated analysis of co-localized protein expression in histologic sections of prostate cancer. PLoS One. 2017; 12(5):e0178362. Tennill TA, Gross ME, Frieboes HB. PMID: 28552967; PMCID: PMC5446169.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    20. Androgen receptor in cancer-associated fibroblasts influences stemness in cancer cells. Endocr Relat Cancer. 2017 04; 24(4):157-170. Liao CP, Chen LY, Luethy A, Kim Y, Kani K, MacLeod AR, Gross ME. PMID: 28264911; PMCID: PMC5453797.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansAnimalsCells
    21. A review of clinical effects associated with metabolic syndrome and exercise in prostate cancer patients. Prostate Cancer Prostatic Dis. 2016 12; 19(4):323-332. Kiwata JL, Dorff TB, Schroeder ET, Gross ME, Dieli-Conwright CM. PMID: 27349496; PMCID: PMC5099103.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimals
    22. Blood-based gene expression profiling in castrate-resistant prostate cancer. BMC Med. 2015 Sep 14; 13:219. Gross ME. PMID: 26365516; PMCID: PMC4568585.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    23. Salvage ablative therapy in prostate cancer: international multidisciplinary consensus on trial design. Urol Oncol. 2015 Nov; 33(11):495.e1-7. van den Bos W, Muller BG, de Bruin DM, de Castro Abreu AL, Chaussy C, Coleman JA, Finelli A, Gill IS, Gross ME, Jenniskens SF, Kahmann F, Laguna-Pes MP, Rastinehad AR, Simmons LA, Sulser T, Villers A, Ward JF, de la Rosette JJ. PMID: 26231310; PMCID: PMC9083830.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    24. Expression and functional role of orphan receptor GPR158 in prostate cancer growth and progression. PLoS One. 2015; 10(2):e0117758. Patel N, Itakura T, Jeong S, Liao CP, Roy-Burman P, Zandi E, Groshen S, Pinski J, Coetzee GA, Gross ME, Fini ME. PMID: 25693195; PMCID: PMC4333349.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansAnimalsCells
    25. A novel technique using three-dimensionally documented biopsy mapping allows precise re-visiting of prostate cancer foci with serial surveillance of cell cycle progression gene panel. Prostate. 2015 Jun; 75(8):863-71. Ukimura O, Gross ME, de Castro Abreu AL, Azhar RA, Matsugasumi T, Ushijima S, Kanazawa M, Aron M, Gill IS. PMID: 25663102.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    26. Trans-rectal ultrasound visibility of prostate lesions identified by magnetic resonance imaging increases accuracy of image-fusion targeted biopsies. World J Urol. 2015 Nov; 33(11):1669-76. Ukimura O, Marien A, Palmer S, Villers A, Aron M, de Castro Abreu AL, Leslie S, Shoji S, Matsugasumi T, Gross M, Dasgupta P, Gill IS. PMID: 25656687; PMCID: PMC9083552.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    27. Radium 223: how can we optimize this new tool for metastatic castration-resistant prostate cancer? Am Soc Clin Oncol Educ Book. 2015; e270-3. Dorff TB, Gross ME. PMID: 25993185.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    28. A Phase II trial of a combination herbal supplement for men with biochemically recurrent prostate cancer. Prostate Cancer Prostatic Dis. 2014 Dec; 17(4):359-65. Dorff TB, Groshen S, Tsao-Wei DD, Xiong S, Gross ME, Vogelzang N, Quinn DI, Pinski JK. PMID: 25245366; PMCID: PMC4234307.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCellsCTClinical Trials
    29. Rapid phenotypic and genomic change in response to therapeutic pressure in prostate cancer inferred by high content analysis of single circulating tumor cells. PLoS One. 2014; 9(8):e101777. Dago AE, Stepansky A, Carlsson A, Luttgen M, Kendall J, Baslan T, Kolatkar A, Wigler M, Bethel K, Gross ME, Hicks J, Kuhn P. PMID: 25084170; PMCID: PMC4118839.
      View in: PubMed   Mentions: 83     Fields:    Translation:HumansCells
    30. Intolerance of uncertainty, cognitive complaints, and cancer-related distress in prostate cancer survivors. Psychooncology. 2015 Feb; 24(2):228-35. Eisenberg SA, Kurita K, Taylor-Ford M, Agus DB, Gross ME, Meyerowitz BE. PMID: 24891013.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    31. Phase I/II trial of orteronel (TAK-700)--an investigational 17,20-lyase inhibitor--in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res. 2014 Mar 01; 20(5):1335-44. Dreicer R, MacLean D, Suri A, Stadler WM, Shevrin D, Hart L, MacVicar GR, Hamid O, Hainsworth J, Gross ME, Shi Y, Webb IJ, Agus DB. PMID: 24418642.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    32. Prostate cancer: Age is nothing but a number. Nat Rev Urol. 2013 12; 10(12):683-4. Gross ME. PMID: 24217679.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    33. Anterior gradient 2 (AGR2): blood-based biomarker elevated in metastatic prostate cancer associated with the neuroendocrine phenotype. Prostate. 2013 Feb 15; 73(3):306-15. Kani K, Malihi PD, Jiang Y, Wang H, Wang Y, Ruderman DL, Agus DB, Mallick P, Gross ME. PMID: 22911164.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCells
    34. Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer. Clin Nucl Med. 2012 Jul; 37(7):637-43. Jadvar H, Desai B, Ji L, Conti PS, Dorff TB, Groshen SG, Gross ME, Pinski JK, Quinn DI. PMID: 22691503; PMCID: PMC3375600.
      View in: PubMed   Mentions: 51     Fields:    Translation:HumansCTClinical Trials
    35. Safety and preliminary efficacy analysis of the mTOR inhibitor ridaforolimus in patients with taxane-treated, castration-resistant prostate cancer. Clin Genitourin Cancer. 2012 Dec; 10(4):232-8. Amato RJ, Wilding G, Bubley G, Loewy J, Haluska F, Gross ME. PMID: 22695254; PMCID: PMC3963491.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    36. Multimodality imaging in biochemical recurrence of prostate cancer: utility of (18)F-NaF PET/CT in early detection of metastasis. Rev Esp Med Nucl Imagen Mol. 2012 Jul-Aug; 31(4):231-2. Desai B, Gross ME, Jadvar H. PMID: 22980132; PMCID: PMC3458514.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    37. Focal cryotherapy for clinically unilateral, low-intermediate risk prostate cancer in 73 men with a median follow-up of 3.7 years. Eur Urol. 2012 Jul; 62(1):55-63. Bahn D, de Castro Abreu AL, Gill IS, Hung AJ, Silverman P, Gross ME, Lieskovsky G, Ukimura O. PMID: 22445223.
      View in: PubMed   Mentions: 65     Fields:    Translation:Humans
    38. Body image predicts quality of life in men with prostate cancer. Psychooncology. 2013 Apr; 22(4):756-61. Taylor-Ford M, Meyerowitz BE, D'Orazio LM, Christie KM, Gross ME, Agus DB. PMID: 22422671.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    39. Quantitative proteomic profiling identifies protein correlates to EGFR kinase inhibition. Mol Cancer Ther. 2012 May; 11(5):1071-81. Kani K, Faca VM, Hughes LD, Zhang W, Fang Q, Shahbaba B, Luethy R, Erde J, Schmidt J, Pitteri SJ, Zhang Q, Katz JE, Gross ME, Plevritis SK, McIntosh MW, Jain A, Hanash S, Agus DB, Mallick P. PMID: 22411897; PMCID: PMC3959865.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimalsCells
    40. Cytometric comparisons between circulating tumor cells from prostate cancer patients and the prostate-tumor-derived LNCaP cell line. Phys Biol. 2012 Feb; 9(1):016002. Lazar DC, Cho EH, Luttgen MS, Metzner TJ, Uson ML, Torrey M, Gross ME, Kuhn P. PMID: 22306736; PMCID: PMC3387997.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansCells
    41. 3-Dimensional elastic registration system of prostate biopsy location by real-time 3-dimensional transrectal ultrasound guidance with magnetic resonance/transrectal ultrasound image fusion. J Urol. 2012 Mar; 187(3):1080-6. Ukimura O, Desai MM, Palmer S, Valencerina S, Gross M, Abreu AL, Aron M, Gill IS. PMID: 22266005.
      View in: PubMed   Mentions: 55     Fields:    Translation:Humans
    42. Safety and pharmacokinetics of high-dose gefitinib in patients with solid tumors: results of a phase I study. Cancer Chemother Pharmacol. 2012 Jan; 69(1):273-80. Gross ME, Leichman L, Lowe ES, Swaisland A, Agus DB. PMID: 22002543.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    43. The epothilones: new therapeutic agents for castration-resistant prostate cancer. Oncologist. 2011; 16(10):1349-58. Dorff TB, Gross ME. PMID: 21964003; PMCID: PMC3228074.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    44. Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer. Urology. 2011 May; 77(5):1166-71. Yu EY, Massard C, Gross ME, Carducci MA, Culine S, Hudes G, Posadas EM, Sternberg CN, Wilding G, Trudel GC, Paliwal P, Fizazi K. PMID: 21539969; PMCID: PMC3394099.
      View in: PubMed   Mentions: 47     Fields:    Translation:HumansCTClinical Trials
    45. Show us a sign: the search for "game changing" prostate cancer biomarkers. Lancet Oncol. 2011 Mar; 12(3):204-6. Quinn D, Gross M. PMID: 21310657.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    46. Beta-2-microglobulin expression correlates with high-grade prostate cancer and specific defects in androgen signaling. Prostate. 2010 Aug; 70(11):1201-10. Mink SR, Hodge A, Agus DB, Jain A, Gross ME. PMID: 20564426.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    47. Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate cancer. Clin Chem. 2010 Sep; 56(9):1492-5. Jiang Y, Palma JF, Agus DB, Wang Y, Gross ME. PMID: 20581083.
      View in: PubMed   Mentions: 57     Fields:    Translation:HumansCells
    48. Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium. Invest New Drugs. 2011 Dec; 29(6):1432-40. Bradley DA, Daignault S, Ryan CJ, Dipaola RS, Cooney KA, Smith DC, Small E, Mathew P, Gross ME, Stein MN, Chen A, Pienta KJ, Escara-Wilke J, Doyle G, Al-Hawary M, Keller ET, Hussain M. PMID: 20336348; PMCID: PMC2917503.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCellsCTClinical Trials
    49. Predictors of affect following treatment decision-making for prostate cancer: conversations, cognitive processing, and coping. Psychooncology. 2009 May; 18(5):508-14. Christie KM, Meyerowitz BE, Giedzinska-Simons A, Gross M, Agus DB. PMID: 18756584.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    50. Rare mutations of the PIK3CA gene in malignancies of the hematopoietic system as well as endometrium, ovary, prostate and osteosarcomas, and discovery of a PIK3CA pseudogene. Leuk Res. 2007 Jan; 31(1):27-32. Müller CI, Miller CW, Hofmann WK, Gross ME, Walsh CS, Kawamata N, Luong QT, Koeffler HP. PMID: 16764926.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCells
    51. Ductal adenocarcinoma of the prostate. Clin Adv Hematol Oncol. 2004 Jun; 2(6):393-5; discussion 396. Shazer RL, Luthringer D, Agus DB, Gross ME. PMID: 16163211.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    52. Targeting the HER-kinase axis in cancer. Semin Oncol. 2004 Feb; 31(1 Suppl 3):9-20. Gross ME, Shazer RL, Agus DB. PMID: 15052539.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansAnimalsCells
    53. Update on HER-kinase-directed therapy in prostate cancer. Clin Adv Hematol Oncol. 2004 Jan; 2(1):53-6, 64. Gross ME, Jo S, Agus DB. PMID: 16163160.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    Mitchell's Networks
    Concepts (275)
    Derived automatically from this person's publications.
    _
    Co-Authors (27)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _